BioMedNewsBreaks

TuesdayMay 12, 2026 9:20 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in BioMedWire Editorial on AI-Powered Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced its placement in a BioMedWire editorial exploring emerging technologies aimed at improving intoxication detection across law enforcement, workplace safety and healthcare settings. The editorial highlights MindBio’s development of an artificial intelligence-driven voice analysis platform designed to detect real-time impairment from short speech samples, positioning the company within a growing movement toward noninvasive diagnostic technologies with potential applications across public safety, regulatory enforcement and health monitoring. To view the full press release, visit https://ibn.fm/Ib2KB About MindBio Therapeutics Corp. MindBio is…

Continue Reading

TuesdayMay 12, 2026 9:10 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining emerging breakthroughs in central nervous system drug delivery and the growing market opportunities tied to overcoming the blood-brain barrier. The editorial highlights Oncotelic’s proprietary intranasal nose-to-brain delivery platform, which is designed to enable rapid, targeted therapeutic access to the brain, positioning the company within a broader industry effort to advance next-generation treatments for neurological disease, biodefense applications and other CNS-related conditions. To view the full press release, visit https://ibn.fm/Y8E3U About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading

MondayMay 11, 2026 1:40 pm

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising.  SureNano Science (CSE: SURE) (OTCQB: SURNF), through subsidiary GlucaPharm Inc., is advancing GEP-44, a patented triple agonist peptide targeting GLP-1 and peptide YY receptors as the global obesity and metabolic disease market continues to expand. The company is pursuing a differentiated approach focused on improved efficacy, tolerability and delivery flexibility in a therapeutic category that has become one of the most commercially significant in modern healthcare, with long-term market projections exceeding $200 billion. SureNano is part of an increasingly competitive GLP-1 landscape led by Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen…

Continue Reading

MondayMay 11, 2026 1:18 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients 

HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs, supporting HeartBeam’s regulatory strategy for a device designed to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection within an established approximately $2 billion patch-based monitoring market.  To view the full press release, visit https://ibn.fm/x7016 About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring…

Continue Reading

MondayMay 11, 2026 10:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Expands AI Voice Diagnostics Platform With Fatigue Detection Technology

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the development of AI-powered fatigue recognition technology that analyzes voice patterns and is intended to be added as a commercial feature to the company’s Edge AI Intoxication Detection Kiosks. Designed for high-risk industries including aviation, road transport and mining, the fatigue detection module complements MindBio’s broader voice-based diagnostics platform aimed at identifying intoxication and neurological impairment, with initial commercial testing of the kiosk platform expected in late second quarter 2026. To view the full press…

Continue Reading

MondayMay 11, 2026 10:00 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is developing an AI-driven voice analysis platform designed to detect drug and alcohol intoxication in real time, addressing growing demand for faster, scalable and noninvasive impairment detection across workplace safety, healthcare and public safety markets. By leveraging speech as a diagnostic biomarker, the company is pursuing a differentiated approach to multisubstance intoxication detection within an evolving AI healthcare landscape that includes HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and…

Continue Reading

MondayMay 11, 2026 9:50 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself within a growing push to overcome one of modern medicine’s most persistent challenges: delivering therapeutics effectively across the blood-brain barrier. Through its proprietary intranasal nose-to-brain delivery platform, the company is pursuing targeted central nervous system applications spanning Alzheimer’s disease and biodefense, reflecting broader industry recognition that delivery technology may be as critical as drug discovery itself. Oncotelic is part of an innovative therapeutic landscape that includes Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO). As the global burden of neurodegenerative disease rises and biodefense…

Continue Reading

MondayMay 11, 2026 9:40 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Candidate Following Andes Hantavirus Incident

NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following the recent Andes hantavirus incident aboard a cruise ship, pointing to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. The company said NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and has demonstrated effectiveness in animal models involving multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox and measles, as it advances development of a platform designed to target a broad range of pathogenic viral infections. To view the full press release, visit https://ibn.fm/OYkof ABOUT…

Continue Reading

ThursdayMay 07, 2026 11:44 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Expands Concierge Cardiology Footprint With Atelier Health Agreement

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care solutions, announced a commercial agreement with Beverly Hills-based concierge medical practice Atelier Health, expanding the company’s launch footprint into Southern California and completing its initial targeted markets alongside New York metro, Dallas and South Florida as it advances commercialization of its cable-free 3D ECG technology for remote cardiac monitoring and preventive cardiology. To view the full press release, visit https://ibn.fm/wwNAd About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting…

Continue Reading

ThursdayMay 07, 2026 11:32 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Clearance for Depression and Suicidality Trial 

NRx Pharmaceuticals (NASDAQ: NRXP) announced that the U.S. Food and Drug Administration cleared the company to initiate a Phase 2/3 clinical trial evaluating NRX-101 in patients with treatment-resistant major depressive disorder and suicidality receiving active or sham transcranial magnetic stimulation, with the study to be conducted by subsidiary NRx Defense Systems and expected to enroll 240 participants across academic, HOPE Therapeutics and military treatment facility sites. To view the full press release, visit https://ibn.fm/DxPva About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders,…

Continue Reading